Terry, There is no question as to the validity of the Iluvien-Medidur concept, in delivering drugs on site with micrograms of therapeutic on a daily basis over years. It just may be the ticket to Dry AMD too. pSivida has said they are interested in pursuing this strategy " on their own". But let's face it, a global partner would go far in creating a financial foundation through the clinical phases. I know that Medidur is what pSivida is driving the developmental narrative with, Something has to give and soon. The Alimera story won't hurt in the least. On a side note, ALIM shares sure looked good last week. GL
Kool. Caught that too. Someone always knows something. Let's not get too excited but it's better up after all the days of uncertainty. I'd like to finally hear of an HSS gig with a big partner. That would move the needle and get the mojo going in the right direction. Funny, heavier than normal volume is 150K shares.
Fair analysis in my opinion. It does come down to sales and Quarterly cash burn. The new IOP study is important but will cost 2.5 Million. Can sales subdue the burn? We'll see. I'll be taking a position in Alimera on the dips and holding through 16' at a minimum. Just got to get through the next couple of weeks with the macro market jitters.
Excellent article indeed guys. That's why Alimera will start looking real good next year from an investment perspective. Buying now would most likely be prudent if you want to stay ahead of the curve. Still, we get knocked around with the rest of the market and the rest of the world. I am however firm in my belief that pSivida technology will bring the big boys to sign on with their technology.
Let's face it, pSivida has not been a great investment over the years. Even anticipated news seldom comes to fruition in a timely manner or not at all. We do however know that the management at pSivida won't blow smoke for fun or to get a short term pop in enthusiasm. So, we wait again for the little bit of news that we've all been waiting for. Who really knows when we'll hear about HSS and the new osteoarthritis implant. Pipeline? What pipeline? As China deteriorates and gives rise to uncertainty on a global level, I'm still picking up some more shares of this little company on this dip. I think we're still way off the radar of most investors and though real light in liquidity, undervalued. I do know that until we reach mid to high $4 bucks, pSivida officers won't receive their stock grants.
Just a bit of info for the longs on this MB. The price for Paul Ashton's 245K shares is $4.47 on July 15th, just past. Our new Board Member...Dr. Barry's 40K shares is $4.77 is exercisable on Sept.8th 15'. Will there be any catalysts going forward to bring our SP to something close to these levels. I think so, and I bet Paul is thinking of his new board member from Boston Scientific. It will be interesting to watch for all of us.
Typical of all the bio's in the eye space. The Gene therapy company is taking their platform back to pre-clinical work. The company stock is down another 20% this morning on the news. With EYEG, ITEK and AAVL all trying to get into the eye space, PSDV is hanging in there in a tough bio market this summer. We know of course, that Paul Ashton's Medidur for small molecules is holding strong with the potential for delivering a myriad of small molecules over years. That just might be the ticket for Dry AMD (4 times bigger than wet AMD). Needless to say, as a company we're not overvalued. Sure, I'd like to hear about the Tethadur platform....but one thing we can be sure of , is that Ashton won't fall into the AAVL hole of insufficient data to support an IND.
It seems Alimera is spending money like drunken sailors. But year over year the market for Iluvien is growing.
And the money that Alimera is spending on the new study to show IOP management and better efficacy is most likely wise. I do not agree with Frank's assertion that ALIM is going under. I think 16' will be very active with it's "J" code issued. I don't remember what the projected numbers were for 15'. But a miss in the quarter
will be absorbed by those willing to pick up the cheap shares and hold for next year. Meanwhile pSivida shareholders are holding their collective positions hoping something breaks on any one of the multiple fronts that may just open up. C'mon HSS news.
Hard to believe. We're already generating revenues that exceed this. We do however need partners. This not only provides developmental support but gives us street cred. Street credibility is very much needed with us. B&L was the last real deal. That was awhile ago. We need to make a move with big pharma support. If it comes we'll let market do the talking. Until then, we need data to give us the backbone moving forward. I'm still way in with pSivida.
Frank, Not yet. We're watching just like you are. I'm just hoping for a partner. Perhaps Zimmer or Stryker would get us noticed in a way we've not been noticed before. Either way, you're right.....summer is running out up here....GL.
The article stated that the company secured 25 Million in financing. That is "NOT" what happened....the company received a 25 Million "milestone" payment. There is "no debt" on pSivida's books, and there is ample cash on hand to take the company into 2017 without receiving any revenue from the Iluvien sales split.
Yeah, like you didn't see this fundraising coming with a major dilution to go with it. They had no cash. Until there is real data this is going much lower.
Terry, I think that this is pSivida's year end ,June 30th. So, we won't report until Sept. It will however be very
interesting to catch Dan Myers on the ALIM call coming up.
In spite of a lack of a J code this year, I bet Iluvien sales are on the rise. It would be nice to
see the EU pick up with Portugal and the UK. France as always is screwed and will continue to be
because, well....it France. When is Australia and New Zealand coming on line with distribution?
A share of the annual Uveitis market share of 175K patients is not a small market. It's a billion dollar market. And, if you've been developing and refining the best delivery system, that lasts for three years and just might prove to be the best therapy for the indication, wouldn't that be worth more than 120Mil MC? The answer is yes. A "TEN" percent share of the market, where there is no drug (other than pSivida's other FDA approved product for the indication) , would be 17.5K @ 8K......well that's $140M annually. This indication alone puts us at 850M MC. Patience all. The first PIII data is March. The FDA might be a bit forgiving with "Kick As*" data on an early approval. And I think the last investigator sponsored "DUKE DATA", kicks but. The trial study that is ongoing may not be curing blindness.....only because that particular patient would not be allowed in the trial. Hang in there guys. This company will rock. Paul Ashton will prove himself on Medidur alone....Uveitis will generate a lot of money......for any acquiring company. Shhhhhh. that doesn't include any interest for the pipeline.
One addition piece of food for thought here; Pfizer recently filed with the SEC, their statement of ownership in pSivida. That hasn't been done in all the years that I've had a position in the company. It was just a restatement of what they owned. I think it was Terry that brought it to light on the MB. Peculiar I'd say. What does it mean? Who knows, but it was a bit odd. I ran that by Beverly....she said she had not seen it restated by Pfizer either , in a very long time. pSivida is caught in a catch 22 here. Our MC is so low, most institutions are prohibited from owning it. Then, our liquidity is so low by our low volume that we not an attractive company to take a position in on the open market, or it would just drive up the price. Then, institutions can't take a position in a secondary because we trade in the Australian market. By rule we can not dilute more than 15% a year. So, we sit at these levels until data drives us higher, then perhaps something good happens. During this whole time we are vulnerable to being pushed up and down on low volume trading. It's all good. Someday we'll get noticed for all the right reasons
Terry, Pfizer splitting into two segments makes sense. Tom brought that up in a post not too far back on this MB. This is where patience as a pSivida shareholder is paramount. "If" pSivida really has the goods to deliver biologics then it is a very worthwhile pursuit for any big pharma. At the same time any acquiring pharma would be getting the Durasert/Medidur platform on the cheap as well. At 120M MC, pSivida is just too undervalued. If it's about data then I'm sure Paul Ashton is doing his best here. Data is everything. Ask the CEO of Avalanche...oh, he resigned.